Literature DB >> 34386906

Novel Therapeutics for Neonatal Seizures.

Julie M Ziobro1, Krista Eschbach2, Renée A Shellhaas3.   

Abstract

Neonatal seizures are a common neurologic emergency for which therapies have not significantly changed in decades. Improvements in diagnosis and pathophysiologic understanding of the distinct features of acute symptomatic seizures and neonatal-onset epilepsies present exceptional opportunities for development of precision therapies with potential to improve outcomes. Herein, we discuss the pathophysiology of neonatal seizures and review the evidence for currently available treatment. We present emerging therapies in clinical and preclinical development for the treatment of acute symptomatic neonatal seizures. Lastly, we discuss the role of precision therapies for genetic neonatal-onset epilepsies and address barriers and goals for developing new therapies for clinical care.
© 2021. The American Society for Experimental NeuroTherapeutics, Inc.

Entities:  

Keywords:  Antiseizure medication; Bumetanide; Hypoxic-ischemic encephalopathy; KCNQ2; Levetiracetam; Phenobarbital

Mesh:

Substances:

Year:  2021        PMID: 34386906      PMCID: PMC8608938          DOI: 10.1007/s13311-021-01085-8

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   6.088


  172 in total

1.  The temporal evolution of electrographic seizure burden in neonatal hypoxic ischemic encephalopathy.

Authors:  Niamh E Lynch; Nathan J Stevenson; Vicki Livingstone; Brendan P Murphy; Janet M Rennie; Geraldine B Boylan
Journal:  Epilepsia       Date:  2012-02-06       Impact factor: 5.864

2.  Design and implementation of electronic health record common data elements for pediatric epilepsy: Foundations for a learning health care system.

Authors:  Zachary M Grinspan; Anup D Patel; Renée A Shellhaas; Anne T Berg; Erika T Axeen; Jeffrey Bolton; David F Clarke; Jason Coryell; William D Gaillard; Howard P Goodkin; Sookyong Koh; Alison Kukla; Juma S Mbwana; Lindsey A Morgan; Nilika S Singhal; Margaret M Storey; Elissa G Yozawitz; Nicholas S Abend; Mark P Fitzgerald; Sara E Fridinger; Ingo Helbig; Shavonne L Massey; Marisa S Prelack; Jeffrey Buchhalter
Journal:  Epilepsia       Date:  2020-12-24       Impact factor: 5.864

3.  Treatment with brivaracetam in children - The experience of a pediatric epilepsy center.

Authors:  Andreea Nissenkorn; Michal Tzadok; Omer Bar-Yosef; Bruria Ben-Zeev
Journal:  Epilepsy Behav       Date:  2019-11-04       Impact factor: 2.937

4.  High seizure load during sensitive periods of development leads to broad shifts in ultrasonic vocalization behavior in neonatal male and female C57BL/6J mice.

Authors:  Suzanne O Nolan; Samantha L Hodges; Siena M Condon; Ilyasah D A Muhammed; Lindsay A Tomac; Matthew S Binder; Conner D Reynolds; Joaquin N Lugo
Journal:  Epilepsy Behav       Date:  2019-04-22       Impact factor: 2.937

5.  Levetiracetam for treatment of neonatal seizures.

Authors:  Nicholas S Abend; Ana M Gutierrez-Colina; Heather M Monk; Dennis J Dlugos; Robert R Clancy
Journal:  J Child Neurol       Date:  2011-01-13       Impact factor: 1.987

6.  Current knowledge for pyridoxine-dependent epilepsy: a 2016 update.

Authors:  Izabella Agostinho Pena; Alex MacKenzie; Clara D M Van Karnebeek
Journal:  Expert Rev Endocrinol Metab       Date:  2016-12-30

7.  Lacosamide improves outcome in a murine model of traumatic brain injury.

Authors:  Bo Wang; Hana Dawson; Haichen Wang; Dawn Kernagis; Brad J Kolls; Lucy Yao; Daniel T Laskowitz
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

Review 8.  Potassium channel genes and benign familial neonatal epilepsy.

Authors:  Snezana Maljevic; Holger Lerche
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

9.  Dose-dependent effects of levetiracetam after hypoxia and hypothermia in the neonatal mouse brain.

Authors:  Katja Strasser; Laura Lueckemann; Verena Kluever; Sinthuya Thavaneetharajah; Daniela Hoeber; Ivo Bendix; Joachim Fandrey; Astrid Bertsche; Ursula Felderhoff-Mueser
Journal:  Brain Res       Date:  2016-05-20       Impact factor: 3.252

10.  Dose-dependent reversal of KCC2 hypofunction and phenobarbital-resistant neonatal seizures by ANA12.

Authors:  B M Carter; B J Sullivan; J R Landers; S D Kadam
Journal:  Sci Rep       Date:  2018-08-10       Impact factor: 4.379

View more
  1 in total

1.  Precision Treatments in Epilepsy.

Authors:  Scott Demarest; Amy Brooks-Kayal
Journal:  Neurotherapeutics       Date:  2021-10-26       Impact factor: 6.088

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.